ArticleBMC pediatrics2026
Diagnosis, management, and clinical outcomes of childhood invasive aspergillosis.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo present our clinical experience in pediatric invasive aspergillosis and to identify independent risk factors and prognostic thresholds affecting survival. MATERIALS AND
methodsWe retrospectively reviewed 30 pediatric patients diagnosed with proven or probable invasive aspergillosis at a tertiary care center between 2012 and 2025. Demographic, clinical, radiological, and laboratory data were analyzed. Receiver Operating Characteristic (ROC) curve analysis was performed to identify optimal prognostic cut-offs for laboratory markers. Multivariate logistic regression was used to identify independent associates of mortality while addressing the risk of overfitting.
resultsThirty patients were included (56.7% male; median age 114.5 months). The most common underlying diseases were hemato-oncological malignancies (53.4%), immunodeficiencies (23.3%), and non-malignant hematological diseases (23.3%). Fifteen patients (50%) were diagnosed with proven IA and 15 (50%) with probable IA. Neutropenia was seen in 22 patients (73.3%) and lymphopenia in 29 (96.7%). Crude and attributable mortality rates were 40% (n = 12) and 13.3% (n = 4), respectively. ROC analysis identified critical thresholds for mortality: ferritin > 3479 ng/mL (AUC: 0.823, p = 0.019), procalcitonin > 7.3 ng/mL (AUC: 0.745, p = 0.025), and absolute monocyte count < 0.01 × 10³/µL (AUC: 0.678, p = 0.048). In this cohort, multivariate analysis indicated that higher baseline ferritin levels were independently associated with increased mortality (OR: 1.12, 95% CI: 1.01-1.26, p = 0.038). However, hyperferritinemia was significantly more pronounced in patients with aplastic anemia (p = 0.001).
conclusionEarly diagnosis and aggressive antifungal therapy appear effective in limiting invasive aspergillosis attributable mortality. The integration of specific laboratory thresholds, particularly high ferritin and profound monocytopenia, may offer valuable insights for risk stratification in pediatric invasive aspergillosis. Future multicenter studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.